Background.The purpose of this study is to understand the oral mucosal immune status of cancer patients and to make clear whether antibacterial proteins such as salivary secretory immunoglobulin (SIgA) and lysozyme in saliva were influenced by patients’ health status and certain medical treatment therapy.Materials and Methods.This study included 221 patients with malignant tumor receiving antineoplastic treatment and 171 age- and gender-matched healthy controls.Results.The results showed that patients suffering malignant tumor had lower level of SIgA and higher level of lysozyme than healthy subjects (P<0.05). The SIgA level was significantly different among different cancer tumors, while the lysozyme level showed significant difference only between patients with digestive tract malignant tumor and hematopoietic system tumor. Pretreatment before transplantation for hematopoietic system tumor patients significantly affected the lysozyme level other than SIgA. SIgA level was affected by many factors such as age, therapy factors, and oral hygiene.Conclusion.Malignant tumor and the antineoplaston may weaken the patients’ oral mucosal immunity, influence levels of some salivary proteins, and decrease the level of SIgA, resulting in aggregation of oral bacteria and failure of clearing them from the oral cavity.

2014-12-01·Child's Nervous System4区 · 医学

Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek

4区 · 医学

Article

作者: Blaskiewicz, Robert

Although Burzynski et al. conclude that antineoplastons are a useful treatment, their results do not adequately support their conclusion, and much of what we know about antineoplastons suggests that antineoplastons can have serious and potentially life-threatening side effects, with no evidence of efficacy that could justify that risk. While many of the problems with the paper will be immediately apparent to readers (for instance, the decision to exclude over half of the patients from analysis), readers should also be aware of the context in which the study, BT-11, was conducted. In the 1990s, when the BT-11 trial was initiated, it was one of over 70 clinical trials of antineoplastons that, according Stanislaw Burzynski’s lawyer, Richard Jaffe, would allow Burzynski “to treat almost any patient Burzynski would want to treat!” In all the years since, not a single one of those 70+ clinical trials has culminated in a meaningful paper. For all intents and purposes, the medical community knows nothing more about antineoplastons than they did when the trials opened, and the current paper does not change that. Over the course of these never-ending and apparently unpublishable clinical trials, the US Food and Drug Administration has periodically inspected the Burzynski Research Institute (BRI) and the principal investigator, Stanislaw Burzynski. The FDA have released the observational notes (form 483s) and other documents from these inspections which specifically refer to BT-11, as well as to studies underway at the BRI concurrently with BT-11 and the BRI Institutional Review Board (IRB) that oversaw all of the studies. They are shocking reading, and detail an unbroken string of abysmal FDA site reviews of the Burzynski Research Institute spanning the last 14 years. For instance, a 483 form 2001 noted that “Subjects were started on antineoplaston treatment prior to the protocol-specified interval following prior chemotherapy and/or radiation therapy,” including a patient participating in trial BT-11, who had too recently been treated with etoposide. During the same visit, inspectors observed that “Not all serious adverse events and adverse events are reported to FDA and IRB,” including two patients in BT-11, including one patient who had to be removed from the chemotherapy all together because of recurring pancreatitis. Inspectors also observed a “failure to address and resolve reported patient overdoses in BRI query reports to determine the reason for the possible overdose and to take corrective action to prevent recurrence,” including two patients in BT-11. Additionally, the files of at least two patients in the BT-11 did not record independent tumor measurements by consultants. In the Establishment Inspection Report, the FDA investigator recorded:

2011-12-02·BMJ

Texan clinic threatens UK bloggers with legal action over criticisms of its treatments

作者: McCartney, M.

A US clinic has issued legal threats to health bloggers in the United Kingdom over their criticisms of its treatments. The Burzynski Clinic in Houston uses antineoplaston treatments, which it says on its website “are based on the natural biochemical defense system of our body, capable of combating cancer without harming the healthy cells.” The clinic was the subject of an article in the Observer newspaper on 20 November (www.guardian.co.uk/theobserver/2011/nov/20/a-family-gripped-by-cancer), written by Luke Bainbridge, a founding editor of Observer Music Monthly , which described a fundraising campaign by Mr Bainbridge to send his 4 year old niece, who has a glioma, to the clinic for treatment. Mr Bainbridge said that fundraising efforts were required for a “pioneering treatment at the Burzynski Clinic in Texas . . . The estimated cost is £200 000 [€235 000; $315 000]. It is not available in this country, it is new and there …

100 项与 Antineoplaston A3 相关的药物交易

登录后查看更多信息